Literature DB >> 27555382

Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation.

Andrew H Miller1, Ebrahim Haroon1, Jennifer C Felger1.   

Abstract

A wealth of data has been amassed that details a complex, yet accessible, series of pathways by which the immune system, notably inflammation, can influence the brain and behavior. These data have opened the window to a diverse array of novel targets whose potential efficacy is tied to specific neurotransmitters and neurocircuits as well as specific behaviors. What is clear is that the impact of inflammation on the brain cuts across psychiatric disorders and engages dopaminergic and glutamatergic pathways that regulate motivation and motor activity as well as the sensitivity to threat. Given the ability to identify patient populations with increased inflammation, the precision of interventions can be further tuned, in conjunction with the ability to establish target engagement in the brain through the use of multiple neuroimaging strategies. After a brief overview of the mechanisms by which inflammation affects the brain and behavior, this review examines the extant literature on the efficacy of anti-inflammatory treatments, while forging guidelines for future intelligent clinical trial design. An examination of the most promising therapeutic strategies is also provided, along with some of the most exciting clinical trials that are currently being planned or underway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27555382      PMCID: PMC5143492          DOI: 10.1038/npp.2016.167

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  236 in total

1.  Oscillations in the basal ganglia.

Authors:  T Wichmann; M R DeLong
Journal:  Nature       Date:  1999-08-12       Impact factor: 49.962

Review 2.  Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders.

Authors:  Hymie Anisman; Zul Merali; Shawn Hayley
Journal:  Prog Neurobiol       Date:  2008-02-13       Impact factor: 11.685

3.  Evidence for increased microglial priming and macrophage recruitment in the dorsal anterior cingulate white matter of depressed suicides.

Authors:  Susana G Torres-Platas; Cristiana Cruceanu; Gary Gang Chen; Gustavo Turecki; Naguib Mechawar
Journal:  Brain Behav Immun       Date:  2014-05-20       Impact factor: 7.217

Review 4.  The role of inflammation in depression: from evolutionary imperative to modern treatment target.

Authors:  Andrew H Miller; Charles L Raison
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

5.  Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice.

Authors:  Stefan O Reber; Philip H Siebler; Nina C Donner; James T Morton; David G Smith; Jared M Kopelman; Kenneth R Lowe; Kristen J Wheeler; James H Fox; James E Hassell; Benjamin N Greenwood; Charline Jansch; Anja Lechner; Dominic Schmidt; Nicole Uschold-Schmidt; Andrea M Füchsl; Dominik Langgartner; Frederick R Walker; Matthew W Hale; Gerardo Lopez Perez; Will Van Treuren; Antonio González; Andrea L Halweg-Edwards; Monika Fleshner; Charles L Raison; Graham A Rook; Shyamal D Peddada; Rob Knight; Christopher A Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

6.  The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine.

Authors:  N Müller; M J Schwarz; S Dehning; A Douhe; A Cerovecki; B Goldstein-Müller; I Spellmann; G Hetzel; K Maino; N Kleindienst; H-J Möller; V Arolt; M Riedel
Journal:  Mol Psychiatry       Date:  2006-02-21       Impact factor: 15.992

7.  A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia.

Authors:  Jeffrey A Lieberman; Geoffrey Dunbar; Anthony C Segreti; Ragy R Girgis; Frances Seoane; Jessica S Beaver; Naihua Duan; David A Hosford
Journal:  Neuropsychopharmacology       Date:  2012-12-18       Impact factor: 7.853

Review 8.  Rescuing CD4+CD25+ regulatory T-cell functions in rheumatoid arthritis by cytokine-targeted monoclonal antibody therapy.

Authors:  Jagadeesh Bayry; Sophie Sibéril; Frédéric Triebel; David F Tough; Srini V Kaveri
Journal:  Drug Discov Today       Date:  2007-06-27       Impact factor: 7.851

9.  Levodopa reverses cytokine-induced reductions in striatal dopamine release.

Authors:  Jennifer C Felger; Carla R Hernandez; Andrew H Miller
Journal:  Int J Neuropsychopharmacol       Date:  2015-01-31       Impact factor: 5.176

Review 10.  The role of immune genes in the association between depression and inflammation: a review of recent clinical studies.

Authors:  Chiara Bufalino; Nilay Hepgul; Eugenio Aguglia; Carmine M Pariante
Journal:  Brain Behav Immun       Date:  2012-05-08       Impact factor: 7.217

View more
  47 in total

1.  Abnormalities in the brain-immune system in psychotic disorders: from pathogenesis to prevention.

Authors:  Kenji Hashimoto
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-08       Impact factor: 5.270

2.  The Immunology of Behavior-Exploring the Role of the Immune System in Brain Health and Illness.

Authors:  Andrew H Miller; Ebrahim Haroon; Jennifer C Felger
Journal:  Neuropsychopharmacology       Date:  2017-01       Impact factor: 7.853

Review 3.  Engineering challenges for brain tumor immunotherapy.

Authors:  Johnathan G Lyon; Nassir Mokarram; Tarun Saxena; Sheridan L Carroll; Ravi V Bellamkonda
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

4.  Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection.

Authors:  Manish K Jha; Abu Minhajuddin; Bharathi S Gadad; Tracy L Greer; Taryn L Mayes; Madhukar H Trivedi
Journal:  Brain Behav Immun       Date:  2017-07-08       Impact factor: 7.217

5.  Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder.

Authors:  Ebrahim Haroon; Alexander W Daguanno; Bobbi J Woolwine; David R Goldsmith; Wendy M Baer; Evanthia C Wommack; Jennifer C Felger; Andrew H Miller
Journal:  Psychoneuroendocrinology       Date:  2018-05-19       Impact factor: 4.905

6.  Granulocyte Colony Stimulating Factor Enhances Reward Learning through Potentiation of Mesolimbic Dopamine System Function.

Authors:  Munir Gunes Kutlu; Lillian J Brady; Emily G Peck; Rebecca S Hofford; Jordan T Yorgason; Cody A Siciliano; Drew D Kiraly; Erin S Calipari
Journal:  J Neurosci       Date:  2018-08-27       Impact factor: 6.167

Review 7.  Brick by Brick: Building a Transdiagnostic Understanding of Inflammation in Psychiatry.

Authors:  David S Thylur; David R Goldsmith
Journal:  Harv Rev Psychiatry       Date:  2022 Jan-Feb 01       Impact factor: 3.732

8.  Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression.

Authors:  Mandakh Bekhbat; Karen Chu; Ngoc-Anh Le; Bobbi J Woolwine; Ebrahim Haroon; Andrew H Miller; Jennifer C Felger
Journal:  Psychoneuroendocrinology       Date:  2018-09-06       Impact factor: 4.905

9.  The hedgehog pathway suppresses neuropathogenesis in CD4 T cell-driven inflammation.

Authors:  Nail Benallegue; Hania Kebir; Richa Kapoor; Alexis Crockett; Cen Li; Lara Cheslow; Mohamed S Abdel-Hakeem; James Gesualdi; Miles C Miller; E John Wherry; Molly E Church; M Andres Blanco; Jorge I Alvarez
Journal:  Brain       Date:  2021-07-28       Impact factor: 13.501

10.  Effects of exogenous ghrelin administration and ghrelin receptor blockade, in combination with alcohol, on peripheral inflammatory markers in heavy-drinking individuals: Results from two human laboratory studies.

Authors:  Mehdi Farokhnia; Jeanelle Portelli; Mary R Lee; Gray R McDiarmid; Vikas Munjal; Kelly M Abshire; Jillian T Battista; Brittney D Browning; Sara L Deschaine; Fatemeh Akhlaghi; Lorenzo Leggio
Journal:  Brain Res       Date:  2020-04-24       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.